1. 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). (24th November 2019) Authors: Wu, Y-L; Mok, T S K; Han, J-Y; Ahn, M-J; Delmonte, A; Ramalingam, S S; Kim, S-W; Shepherd, F A; Laskin, J; He, Y; Akamatsu, H; Theelen, W S M E; Su, W-C; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Papadimitrakopoulou, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗